AI Article Synopsis
- Vascular calcification is a major risk factor for heart disease and mortality, especially in hemodialysis patients, and is linked to vitamin D deficiency.
- A clinical trial involving 60 hemodialysis patients tested the effects of oral cholecalciferol (vitamin D3) compared to a placebo over three months, measuring various serum levels.
- Results showed that cholecalciferol significantly increased serum vitamin D and fetuin-A levels without any adverse effects, indicating its potential as a safe treatment for vitamin D deficiency in this patient group.
Article Abstract
Background And Aim: Vascular calcification is an independent risk factor for cardiovascular diseases and all-cause mortality in end stage renal disease, and particularly in hemodialysis patients. Vitamin D deficiency has been shown to be associated with vascular calcification among this category of patients. Cholecalciferol or vitamin D3; the native inactivated 25-hydroxy vitamin D [25(OH)D], has been proposed to have a good impact on vascular calcification and vitamin D deficiency. However, clinical data is still limited.
Methods And Results: A prospective, randomized, placebo-controlled study was carried out to evaluate the effect of oral cholecalciferol on vascular calcification and 25(OH)D levels in hemodialysis patients. A total of sixty eligible hemodialysis patients were randomly assigned to either a treatment group (Oral 200.000IU Cholecalciferol per month) or a placebo group, for 3 months. Serum 25-hydroxy vitamin D (25(OH)D), fetuin-A, fibroblast growth factor (FGF-23), osteoprotegerin (OPG), calcium, phosphorus, their product (CaXP) and intact parathyroid hormone (iPTH) levels, were all assessed at baseline and at the end of the study. ClinicalTrials.gov registration number: NCT03602430. Cholecalciferol significantly increased serum levels of 25(OH)D and fetuin-A in the treatment group (p-value < 0.001), while no significant difference was observed in the placebo group. Cholecalciferol administration showed no effect on either FGF-23 or OPG. None of the treatment group patients experienced any adverse effects.
Conclusion: Cholecalciferol was shown to be an effective, tolerable, inexpensive pharmacotherapeutic option to overcome vitamin D deficiency, with a possible modulating effect on fetuin-A, among hemodialysis patients. CLINICALTRIALS.
Gov Registration Number: NCT03602430.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.numecd.2020.09.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anatomy of Risk: Decoding the Predictors of Vascular Access Complications in Transcatheter Aortic Valve Replacement.
Catheter Cardiovasc Interv
December 2024
Department of Surgery, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, United States.
Background: Despite advancements in valve implantation devices, vascular access complications (VAC) remain a significant cause of morbidity and mortality for those undergoing transcatheter aortic valve replacement (TAVR). We describe pre-operative imaging analysis of the aortoiliac and femoral arterial beds using the TransAtlantic intersociety consensus (TASC) score, ilio-femoral tortuosity, and procedural characteristics to identify anatomic risk factors predictive of VAC in TAVR.
Methods: Consecutive patients undergoing TAVR from 2012 to 2022 at a single North Dakota hospital were retrospectively reviewed.
Prognostic value of toe pressure measurements in patients with diabetic foot ulcers and medial arterial calcification.
Ann Vasc Surg
December 2024
Department of Vascular Surgery, Haga Teaching Hospital, the Hague, the Netherlands.
Objectives: Diabetic foot ulcers (DFU) are one of the most serious chronic diabetes related complications. Since medial arterial calcification (MAC) can be present in patients with a DFU, toe pressure (TP) measurements are advised to grade potential ischemia. However, the value of TP to predict clinical outcomes in this group of patients is poorly understood.
View Article and Find Full Text PDFWhy Current Detection of Vascular Calcification Falls Short and How to Improve on It.
TH Open
October 2024
Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
Vascular calcification is a common phenomenon in various vascular diseases, where its presence heralds increased occurrence of adverse disease events, which invariably lead to increased morbidity and mortality in patients. Although the impact of calcification has become apparent, adequate and early detection of the most damaging form of early microcalcification is still in its infancy, preventing reliable identification of locations that would benefit from intervention. In this review, we will provide an overview of the current state-of-the-art noninvasive calcification imaging and its persisting limitations.
View Article and Find Full Text PDFBrain macrophages in vascular health and dysfunction.
Trends Immunol
December 2024
Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. Electronic address:
Diverse macrophage populations inhabit the rodent and human central nervous system (CNS), including microglia in the parenchyma and border-associated macrophages (BAMs) in the meninges, choroid plexus, and perivascular spaces. These innate immune phagocytes are essential in brain development and maintaining homeostasis, but they also play diverse roles in neurological diseases. In this review, we highlight the emerging roles of CNS macrophages in regulating vascular function in health and disease.
View Article and Find Full Text PDFPrognostic value of coronary artery calcium scoring in patients with non-small cell lung cancer using initial staging computed tomography.
BMC Med Imaging
December 2024
Department of Radiology, Cardiothoracic Imaging, University of Utah, 30 N 1900 E #1A71, Salt Lake City, Utah, 84132, USA.
Background: Lung cancer is a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) comprising 85% of cases. Due to the lack of early clinical signs, metastasis often occurs before diagnosis, impacting treatment and prognosis. Cardiovascular disease (CVD) is a common comorbidity in lung cancer patients, with shared risk factors exacerbating outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!